News
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback